Teva Pharmaceutical Industries Limited
$40.65B- Market cap
- $42.38B
- Debt
- +$1.82B
- Cash
- −$3.56B
Capital structure 96% equity / 4% debt · EV / Revenue 2.36x · EV / EBITDA 9.92x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: TEVA stock price near parity vs SQM $36.37 current versus $38.57 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SQM's multiple
Implied fair value · at TEVA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TEVA FY 2025 (ended Dec 31, 2025) · SQM FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 2.36x · EV / EBITDA 9.92x
Capital structure 77% equity / 23% debt · EV / Revenue 5.46x · EV / EBITDA 27.82x
TEVA carries the larger enterprise value at $40.65B against $24.74B; TEVA trades on the lower EV / Revenue multiple (2.36x vs 5.46x); TEVA on the lower EV / EBITDA (9.92x vs 27.82x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CHEMICAL & MINING CO OF CHILE INC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.23x
—
Net debt / EBITDA
Leverage against operating earnings
-0.42x
5.20x
Cash and equivalents
Liquid reserves on the balance sheet
$3.56B
$1.38B
Total debt
Interest-bearing obligations outstanding
$1.82B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$6.00B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.